Clinical Trial Update: A Study of Palifosfamide Tris Plus Doxorubicin Versus Doxorubicin in Unresectable or Metastatic Soft-tissue Sarcoma [Phase 2]

View source ↗

Summary

Phase 2 clinical trial update comparing Palifosfamide Tris plus Doxorubicin versus Doxorubicin in unresectable or metastatic soft-tissue sarcoma.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Soft Tissue Sarcoma

Drugs mentioned

• Doxorubicin (doxorubicin)
• Palifosfamide Tris (palifosfamide tris)

Snippet

Sponsor: Alaunos Therapeutics | Conditions: Soft Tissue Sarcoma | Phase 2 | Status: UNKNOWN